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Abstract
We report the concise, biomimetic total synthesis of the dimeric, Diels–Alder natural product 
griffipavixanthone from a readily accessible prenylated xanthone monomer. The key step utilizes a 
novel intermolecular [4+2] cycloaddition–cyclization cascade between a vinyl p-quinone methide 
and an in situ generated isomeric diene promoted by either Lewis or Brønsted acids. Experimental 
and computational studies of the reaction pathway suggest that a stepwise, cationic Diels–Alder 
cycloaddition is operative.
Dimeric xanthones are a class of natural products with a wide range of structural diversity 
and biological activity, which underscores these compounds as attractive synthetic targets.1 
Among these compounds, griffipavixanthone (1) possesses a unique structure wherein the 
monomeric tetrahydroxyxanthone units are linked via an apparent Diels–Alder-derived 
bicyclic framework rather than the commonly encountered aryl–aryl or C–O bond (Figure 
1).2 Several related dimeric Diels–Alder xanthones, namely garciobioxanthone (2),3 
bigarcinenone B,4 and garcilivins A and C (not shown),5 wherein the monomeric xanthone 
units are linked by a single cyclohexene ring, have also been isolated and characterized.
Although biological activities of these dimeric xanthones have not been extensively 
reported, 1 is reported to possess antioxidant properties,6 highlighted by in vitro inhibition 
observed against xanthine oxidase.7 In addition, 1 is active against several cancer cell 
*Corresponding Author. porco@bu.edu.
ORCID 
Kyle D. Reichl: 0000-0001-7779-0846
Michael J. Smith: 0000-0002-0389-6864
John A. Porco Jr.: 0000-0002-2991-5680
ASSOCIATED CONTENT
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.7b09265.
Experimental details, computational data, and characterization data for new compounds (PDF)
X-ray crystallographic data for 11a (CIF)
The authors declare no competing financial interest.
HHS Public Access
Author manuscript
J Am Chem Soc. Author manuscript; available in PMC 2018 October 11.
Published in final edited form as:





















lines,2,8,9 and has recently been shown to downregulate the RAF pathway in esophageal 
cancer cells.10 Herein, we report the first chemical synthesis of 1 utilizing a biomimetic 
[4+2] cycloaddition–cyclization cascade between a monomeric, vinyl p-quinone methide (p-
QM) dienophile and an in situ generated, isomeric diene promoted by either zinc(II) iodide 
(ZnI2) or trifluoroacetic acid (TFA).
Biosynthetically, the cyclohexene core of 1 is likely formed via Diels–Alder cycloaddition 
between a prenylated tetrahydroxyxanthone and a related, formally dehydrogenated 1,3-
butadiene,2 both of which may be derived in nature from the monomer garcinexanthone C.11 
With our continuing interest in biomimetic syntheses of Diels–Alder natural products, this 
insight inspired us to consider development of a novel reaction cascade wherein both diene 
and dienophile could be generated from a single prenylated monomer.12 Retrosynthetically, 
we envisioned that 1 may be accessed via intramolecular arylation between the p-QM and 
xanthone moieties of cycloadduct 3 (Scheme 1).13,14 p-QM 3 may be derived from oxidation 
of monomer 6 and subsequent [4+2] cycloaddition of the resulting vinyl p-QM 4 with the 
corresponding isomeric diene 5 generated in situ (vide inf ra).15
To test our biomimetic proposal, we first prepared the requisite prenylated xanthone 
monomer (Scheme 2). Condensation of 1,3,5-trimethoxybenzene with 2,3-dihydroxy-4-
methoxybenzoic acid in the presence of Eaton’s reagent at elevated temperature readily 
provided the desired xanthone as a mixture of 5-hydroxy- and 5-mesyloxyxanthones.16 
Treatment of this crude mixture with methanolic potassium hydroxide allowed for smooth 
demesylation and isolation of the xanthone as the corresponding potassium salt, which was 
subsequently O-alkylated with prenyl bromide to afford prenyloxyxanthone 7 (53% yield, 3 
steps) on a decagram scale. Thermal rearrangement of 7 in refluxing N,N-dimethylaniline 
(DMA) provided the prenylxanthone monomer 8 in 47% yield.17
Our preliminary efforts toward assessing oxidation and isomerization of the key monomeric 
vinyl p-QM intermediate first focused on trimethoxyxanthone substrate 8 in order to 
eliminate potential side reactions resulting from multiple unprotected phenols. We found that 
silver(I) oxide (Ag2O) cleanly oxidized 8 to the desired p-QM 9 at ambient temperature in 
CH2Cl2 as solvent (Scheme 3).18 While treatment of 9 with silica gel, conditions known to 
isomerize prenylated o-quinones to p-QMs,19 typically led to complex product mixtures, 
exposure of 9 to catalytic amounts ofN,N-diisopropylethylamine (DIPEA) promoted smooth 
conversion to 1,3-butadiene 10.20 To the best of our knowledge, this represents the first 
example of isomerization of a vinyl p-QM to the corresponding diene; however, analogous 
formal dehydrogenation of prenylated derivatives to 1,3-butadienes has previously been 
reported.21
The isomerization of 9 to 10 permitted exploration of the proposed [4+2] cycloaddition. 
During isomerization experiments, only trace cycloaddition products were observed, even at 
elevated temperatures. Furthermore, conversion of 9 to 10 did not appear to be reversible 
under the isomerization conditions. These observations led us to conclude that activation of 
9 was necessary for cycloaddition and the rate of cycloaddition must be faster than the 
conversion of 9 to 10.
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To address these requirements, Lewis22 or Brønsted23 acid promoters appeared to be 
required, as they have been shown to activate p-QMs toward subsequent reactivity. Indeed, 
exposure of 9 to catalytic amounts of a number of Lewis acids led to complete consumption 
of starting material (CH2Cl2 as solvent) as determined by 1H NMR analysis.24 Although 
conversion of 9 led to numerous reaction products under many of these conditions, the 
unequal formation of two products with doublets at δ 8.74 and 8.46 ppm (1H NMR) 
suggested formation of p-QM-containing cycloadducts with varying levels of 
diastereoselectivity.24 Full spectroscopic characterization revealed that these species were 
indeed the desired [4+2] cycloadducts. After screening both Lewis acid and solvent, we were 
able to generate isolable quantities of each cycloadduct (Scheme 4). For example, use of 
lanthanum(III) triflate (La(OTf)3) as catalyst in a 2:1 mixture of CH2Cl2 and 
hexafluoroisopropanol (HFIP) with DIPEA as additive at 30 °C selectively provided 
cycloadduct 11a possessing an anti stereochemical relationship of the aromatic ring systems 
in 25% yield. The structure of 11a was confirmed via single-crystal X-ray analysis (Figure 
2) and reveals a significant deviation from planarity (21.3°) between the exocyclic alkene of 
the p-QM and the neighboring carbonyl. Use of ZnI2 resulted in the highest selectivity and 
yield for the diastereomeric syn-cycloadduct 11b (crude ratio 11b:11a = 1.0:0.96) providing 
11b and 11a in 17 and 18% yields, respectively. Furthermore, cycloadduct 11a was found to 
be unreactive to treatment with ZnI2, with no evidence of cycloadduct reversibility or 
epimerization, suggesting metal-ion-dependent stereoselectivity to access 11a/b from 9.24
While numerous Lewis acids generated 11b to varying degrees, subsequent arylation to yield 
the griffipavixanthone core was not readily observed beyond trace quantities. We therefore 
aimed to improve the Zn(II)-catalyzed conditions which provided the highest observed 
selectivity for 11b, and develop a one-pot cycloaddition–cyclization cascade. After 
examining numerous conditions, we determined 9 to be a poor substrate for the desired 
transformation, which required 30 mol% of ZnI2 and elevated (50 °C) temperature in 1,2-
dichloroethane (DCE) to provide griffipavixanthone hexamethyl ether 12 in 4% yield 
(Scheme 5). We considered that the low yields may in part be due to intermolecular arylation 
of the electron-rich ring of 9 and the quinone methide moiety of a second molecule of 9, as 
intermolecular arylations of p-QMs with electron-rich aromatics in the presence of Lewis 
acids have been reported.25,26 Indeed, reaction of 9 with excess 1,3,5-trimethoxybenzene in 
the presence of ZnI2 cleanly afforded 1,6-arylation product 13 in 68% yield (eq 1).
(1)
To address this issue, we hypothesized that demethylation of 9 ortho to the xanthone 
carbonyl would remove electron density from the phloroglucinol-type ring through hydrogen 
bonding, thereby reducing this decomposition pathway. Indeed, we found that the di-O-
methyl-protected vinyl p-QM 1424 was superior to 9, requiring only 15 mol% of ZnI2 at 
40 °C for 16 h in DCE (0.05 M) to provide griffipavixanthone tetramethyl ether 15 in 15% 
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isolated yield. With increased amounts of precursor 15 in hand, full demethylation to (±)-1 
was achieved in 32% yield using a modified potassium carbonate/p-thiocresol protocol in 
N,N-dimethylacetamide (N,N-DMA) as solvent (Scheme 5).27 Spectral data for synthetic 
(±)-1 were in agreement with data previously reported for the natural product.2
In an effort to understand the direct conversion of 14 to 15, experiments designed to 
interrogate the reactivity of cycloadduct intermediates leading to 15 were performed. We 
found that treatment of monomer 14 with 15 mol% of LaCl3·2LiCl provided cycloadducts 
16a/b in 32% combined yield (crude ratio of 16a:16b = 1.5:1.0) with minimal conversion to 
15 observed. Spectral characterization and comparison with 11a/b revealed that anti-
cycloadduct 16a was the major product formed upon reaction of 14 with both LaCl3·2LiCl 
and ZnI2, in contrast with that of 9. Furthermore, cycloadducts 16a/b were found to be 
substantially more reactive than 11a/b, as treatment of both 16a and 16b with 30 mol% ZnI2 
led to 15 in 73% (brsm) and 80% isolated yield, respectively (Scheme 6). Similar results 
were also observed in the presence of 30 mol % of TFA, as both 16a and 16b yielded 15 in 
78% and 82% yield, respectively.28 In light of these results, we anticipated that 14 may also 
yield 15 under similar conditions. Indeed, treatment of 14 with 30 mol% of TFA at 35 °C for 
18 h provided 15 in an improved 21% isolated yield, demonstrating that both Lewis and 
Brønsted acids are capable of promoting the observed cycloaddition–cyclization cascade to 
yield the griffipavixanthone core from monomer 14.
The formation of griffipavixanthone precursor 15 from either 14 or a 16a/b mixture (cf. 
Scheme 6) supports an ionic Diels–Alder reaction cascade in which six-membered ring 
formation is reversible.29,30 Figure 3 outlines a plausible mechanism which is supported by 
DFT computations.24,31,32 After acid-catalyzed isomerization of 14 to 10a, the intermediate 
cation 17 may combine with 10a to afford allylic cations, represented as 18a–c. Cation 18a 
was the lowest energy structure located; this should interconvert with an energetically 
favorable xanthonium ion 19 which arises from capture of the benzyl cation by the 
nucleophilic carbonyl of the pendant xanthone. Isomeric allyl cations 18b and 18c were 
found to possess the correct stereochemistry and conformation required to reversibly 
progress to stereoisomeric benzyl cation intermediates 20 and 21 with barriers of 9.2 and 
17.5 kcal/mol, respectively. The cascade is completed by intramolecular arylation to yield 
arenium ions 22 or 23 through TS4 or TS5, respectively. Selective formation of 
griffipavixanthone precursor 22 vs epimer 23 is consistent with the lower predicted barrier 
(16.5 vs 21.0 kcal/mol) for the irreversible arylation step. This difference is ascribed in part 
to the lower strain energy required to yield the cis- vs trans-fused polycyclic ring systems of 
22 and 23. We note that while these computational results are in agreement with our 
experimental findings, we cannot at this time rule out alternative stereochemical 
interconversion of 16a and 16b via elimination followed by regioselective protonation or 
1,2-hydride shift33 pathways of intermediates 20 and 21.
In summary, we have developed the first synthesis of the Diels–Alder natural product 
griffipavixanthone (1) in racemic form. The unique polycyclic core of 1 was prepared under 
mild Lewis or Brønsted acidic activation via a multistep, one-pot [4+2] cycloaddition–
cyclization cascade involving (1) isomerization of an isolable vinyl p-QM monomer to the 
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corresponding 1,3-butadiene in situ; (2) stepwise, reversible cationic [4+2] cycloaddition 
between the vinyl p-QM monomer and newly generated 1,3-butadiene; and (3) 
intramolecular arylation of a p-QM-containing cycloadduct. Experimental and 
computational investigations of the reaction mechanism support the proposed cationic 
reaction cascade. Further studies related to the asymmetric synthesis of griffipavixanthone 
are under investigation and will be reported in due course.
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Structures of dimeric xanthones.
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X-ray crystal structure of cycloadduct 11a.
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Computational modeling (B3LYP/6-31G(d)) for Brønsted acid-catalyzed reactions. All free 
energies in kcal/mol relative to 18a. See Supporting Information for full reaction coordinate 
diagram.
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Scheme 1. Retrosynthetic Analysis for Griffipavixanthone
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Scheme 2. Synthesis of Xanthone Monomer 8a
aReagents and conditions: (a) Eaton’s reagent, 110 °C, 5.5 h; (b) KOH (8.0 equiv), MeOH, 
rt, 15 h; (c) prenyl bromide (1.6 equiv), K2CO3 (0.21 equiv), DMF, 50 °C, 4 h; (d) DMA, 
194 °C, 2 h.
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Scheme 3. Synthesis and Isomerization of p-QM 9a
aReagents and conditions: (a) Ag2O (1.20 equiv), CH2Cl2, rt, 16 h; (b) DIPEA (0.15 equiv), 
CH2Cl2, rt, 48 h.
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Scheme 4. Lewis Acid-Controlled Dimerization of 8 to Cycloadducts 11a and 11b
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Scheme 5. One-Pot Dimerization–Cyclization Cascade and Demethylation of 15 to (±)-1a
aReagents and conditions: (a) ZnI2 (30 mol%), DCE, 50 °C, 24 h; (b) ZnI2 (15 mol%), DCE, 
40 °C, 16 h; (c) p-MeC6H4SH (10.0 equiv), K2CO3 (1.0 equiv), N,N-DMA, 166 °C, 1.5 h.
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Scheme 6. Conversion of Cycloadducts 16a and 16b and 14 to 15 with Lewis and Brønsted Acids
aReagents and conditions: (a) ZnI2 (30 mol%), CH2Cl2, 35 °C, 7 h (73% yield brsm from 
16a, 80% from 16b); (b) TFA (30 mol%), CH2Cl2, rt, 7 h (78% yield from 16a, 82% from 
16b); (c) TFA (30 mol%), CH2Cl2, 35 °C, 18 h (21% yield).
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